Reading view
Data-Chain Backdoor: Do You Trust Diffusion Models as Generative Data Supplier?
AI4EOSC: a Federated Cloud Platform for Artificial Intelligence in Scientific Research
Toward Closed-loop Molecular Discovery via Language Model, Property Alignment and Strategic Search
Voice-Interactive Surgical Agent for Multimodal Patient Data Control
First, do NOHARM: towards clinically safe large language models
ValuePilot: A Two-Phase Framework for Value-Driven Decision-Making
A data-physics hybrid generative model for patient-specific post-stroke motor rehabilitation using wearable sensor data
COMMA: A Communicative Multimodal Multi-Agent Benchmark
From Clicks to Preference: A Multi-stage Alignment Framework for Generative Query Suggestion in Conversational System
Grounding Large Language Models in Clinical Evidence: A Retrieval-Augmented Generation System for Querying UK NICE Clinical Guidelines
H&E-based MSI/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluation
npj Digital Medicine, Published online: 15 December 2025; doi:10.1038/s41746-025-02218-5
H&E-based MSI/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluationFrom Verification Burden to Trusted Collaboration: Design Goals for LLM-Assisted Literature Reviews
Stakeholder Criteria for Trust in Artificial Intelligence–Based Computer Perception Tools in Health Care: Qualitative Interview Study
Pancreatic Cancer Organoids: Modeling Disease and Guiding Therapy
Cancers (Basel). 2025 Nov 30;17(23):3850. doi: 10.3390/cancers17233850.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. An unmet need exists for reliable biomarkers and in vitro models capable of predicting patient drug response to advance personalized medicine. Traditional models fail to represent the tumor's complexity and the role of the stromal environment in chemoresistance. Patient-derived organoids (PDOs) overcome these limitations, enabling multi-omics profiling and reliable drug testing for functional precision medicine. This review provides a comprehensive overview of PDAC PDO research, emphasizing the following major areas: (i) the genetic and phenotypic fidelity of PDOs, (ii) their predictive value for drug response and chemoresistance, (iii) the integration of the extracellular matrix and tumor microenvironment (TME) components, and (iv) emerging technologies. Studies confirm that PDOs faithfully represent the primary tumor's specific genetic features and retain intratumoral heterogeneity. PDO-based platforms have demonstrated a strong correlation between in vitro drug sensitivity and in vivo efficacy in xenograft models, validating their utility for identifying drug candidates, repurposing existing drugs, and determining effective combinations. Efforts are ongoing to integrate crucial TME components, like cancer-associated fibroblasts, using innovative co-culture platforms such as fused PDOs and InterOMaX, to better model desmoplasia and chemoresistance mechanisms. Furthermore, PDO technology is converging with microphysiological systems and artificial intelligence tools to facilitate high-throughput drug screening and dynamic, real-time monitoring of therapeutic effects. The integration of PDOs into biobanks and advanced screening platforms holds the potential to accelerate drug discovery and improve therapeutic outcomes for PDAC patients, if challenges related to protocol standardization and regulatory acceptance are addressed.
PMID:41375051 | PMC:PMC12690986 | DOI:10.3390/cancers17233850
Toward an AI Reasoning-Enabled System for Patient-Clinical Trial Matching
Multi-Agent Intelligence for Multidisciplinary Decision-Making in Gastrointestinal Oncology
Somatic evolution following cancer treatment in normal tissue
Nature, Published online: 10 December 2025; doi:10.1038/s41586-025-09792-4
High-depth sequencing of non-cancerous tissue from patients with metastatic cancer reveals single-base mutational signatures of alcohol, smoking and cancer treatments, and reveals how exogenous factors, including cancer therapies, affect somatic cell evolution.